ANEBPNKHealthcare

Anebulo Pharmaceuticals, Inc.

-43.5% · 90d

$0.48

+0.00 (+0.63%)

News

No News Yet

Press releases and SEC filings for ANEB will appear here as they are published.

Check back later for updates

Key Data

Market Cap$19.7M

Open$0.52

Prev Close$0.48

Day Range$0.44 – $0.52

52W Range$0.30 – $3.42

Volume1,513

P/E (TTM)—

EPS$-0.18

Dividend Yield—

Beta-1.61

Analyst Ratings

Hold1 analysts

Buy 0Hold 1Sell 0

About

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.

Healthcare · Biotechnology

2 employees

www.anebulo.com